Modular Medical, Inc. — Form 10-K Summary
Period: Fiscal year ended March 31, 2019, compared with fiscal 2018. Although the request metadata refers to “2018 Q4,” this filing is an annual report, not a quarterly filing.
Business context
Modular Medical is a development-stage medical-device company focused on designing an insulin pump intended to provide basal and bolus insulin delivery with simpler operation and lower cost. The company reported no revenue and is focused on product development; an early prototype exists, but the filing says it requires further modification, including safety and manufacturing work. The company anticipates that FDA review will require the more costly and lengthy premarket approval (PMA) pathway.
Financial results and liquidity
| Metric | FY ended March 31, 2019 | FY ended March 31, 2018 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1,882,345 | $332,642 |
| Total operating expenses | $2,577,299 | $666,164 |
| Operating loss | $(2,577,299) | $(666,164) |
| Interest income | $39,390 | $8,518 |
| Net loss | $(2,539,498) | $(659,246) |
| Basic and diluted loss per share | $(0.153) | $(0.049) |
| Cash used in operating activities | $(1,807,934) | $(791,131) |
| Cash and cash equivalents at year-end | $6,553,768 | $4,296,676 |
| Working capital at year-end | $6,390,429 | $4,298,009 |
| Total current liabilities at year-end | $178,929 | $15,471 |
No revenue or profit margins were reported, so margins are not meaningful. The filing reports no material debt; year-end liabilities were current accounts payable and accrued expenses, with no related-party payable remaining. FY2019 financing cash flow was $4,142,150, principally from the 2018 private placement. The company says it expects to seek further equity financing to fund operations.
Material changes versus prior year
- Net loss rose to $2.54 million from $0.66 million, primarily reflecting higher development spending.
- R&D expense increased to $1.88 million from $0.33 million as engineering staffing and outside development costs grew. Management expects R&D spending to continue increasing.
- General and administrative expense, including depreciation, rose to $434,558 from $100,561, primarily due to employee-related costs.
- Operating cash use more than doubled. Cash nevertheless increased, supported by the fiscal 2019 stock placement.
- The company sold 1,856,988 shares at $2.25 per share in its 2018 private placement, reporting gross proceeds of $4,142,666. Shares outstanding increased from 15,983,273 at March 31, 2018 to 17,840,261 at March 31, 2019.
Outlook, risks, and unusual items
- Funding and execution: The company has no operating revenue to fund expenses and anticipates raising additional capital. Product development, regulatory review, and commercialization may require more time or funding than expected.
- Regulatory and product risk: FDA clearance or approval is not assured; the company anticipates a PMA application. Approval could be delayed or denied, and additional clinical, safety, or manufacturing requirements could increase costs.
- Competition and intellectual property: Medtronic, Tandem Diabetes Care, and Insulet have substantially greater resources. Two U.S. patent applications are pending; issuance and competitive protection are not assured.
- Control weakness: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to inadequate controls and lack of segregation of duties. The company reported no separate audit committee or independent director at that time and said it hired a full-time Accounting Manager after year-end.
- Equity compensation: Stock-based compensation expense was $532,108 in FY2019. The filing reports options outstanding and exercisable of 918,020 at March 31, 2019, while separately stating 1,529,908 options had been granted under the plan; reconcile the disclosures when reviewing potential dilution.
- Related-party arrangements: Founder and CEO Paul DiPerna receives royalties on future product sales, subject to a $10 million cap. His employment agreement provides for salary and potential stock-option and discretionary bonus compensation.
- Trading and ownership: Shares trade on the OTC Pink market with limited and sporadic trading. The filing reports substantial ownership concentration among the CEO and affiliated holders.
- The independent auditor issued an unqualified opinion on the financial statements; the auditor did not audit or express an opinion on internal control effectiveness.
Important facts for investors to verify
- Current product-development status, expected FDA pathway, testing requirements, timeline, and remaining funding needs.
- Cash balance and operating burn after March 31, 2019, and the terms and availability of any subsequent financing.
- Reconciliation of option grants, options outstanding, stock-based compensation, and potential dilution.
- Progress in remediating the reported material weakness and whether the new accounting manager and procedures improved controls.
- Share-count disclosures: 17,840,261 shares at March 31, 2019 versus 17,870,261 reported as of June 19, 2019, following a stated 30,000-share issuance.
- Terms and potential impact of the CEO royalty and employment arrangements, and the concentration of voting and beneficial ownership.